Legis Daily

IMPROVE Act

USA115th CongressHR-7217| House 
| Updated: 12/12/2018
Joe Barton

Joe Barton

Republican Representative

Texas

Cosponsors (8)
Brett Guthrie (Republican)Debbie Dingell (Democratic)Gus M. Bilirakis (Republican)Fred Upton (Republican)Gene Green (Democratic)Anna G. Eshoo (Democratic)Kathy Castor (Democratic)Jaime Herrera Beutler (Republican)

Ways and Means Committee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act or the IMPROVE Act This bill establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate. The bill also makes a series of reductions relating to federal Medicaid expenditures. Among other changes, the bill reduces the federal matching rate for states that do not have required asset-verification programs for determining Medicaid eligibility. Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly). Finally, the bill excludes specified wheelchairs and associated accessories from Medicare's competitive acquisition program (in which rates are set through a competitive bidding program rather than by an established fee schedule).

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 6, 2018
Introduced in House
Dec 6, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 11, 2018
Mr. Barton moved to suspend the rules and pass the bill.
Dec 11, 2018
Considered under suspension of the rules. (consideration: CR H10043-10052)
Dec 11, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 7217.
Dec 11, 2018
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Dec 11, 2018
Considered as unfinished business. (consideration: CR H10083)
Dec 11, 2018
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 400 - 11 (Roll no. 428). (text: CR H10043-10047)
View Vote
Dec 11, 2018
Motion to reconsider laid on the table Agreed to without objection.
Dec 12, 2018
Received in the Senate.
  • December 6, 2018
    Introduced in House


  • December 6, 2018
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • December 11, 2018
    Mr. Barton moved to suspend the rules and pass the bill.


  • December 11, 2018
    Considered under suspension of the rules. (consideration: CR H10043-10052)


  • December 11, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 7217.


  • December 11, 2018
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • December 11, 2018
    Considered as unfinished business. (consideration: CR H10083)


  • December 11, 2018
    On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 400 - 11 (Roll no. 428). (text: CR H10043-10047)
    View Vote


  • December 11, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • December 12, 2018
    Received in the Senate.

Health

Related Bills

  • S 115-3702: A bill to amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
  • HR 115-7223: To amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
Birth defectsBlood and blood diseasesBusiness recordsCardiovascular and respiratory healthChild healthCivil actions and liabilityDisability and paralysisEmergency medical services and trauma careFamily servicesHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth personnelHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesHereditary and development disordersHIV/AIDSHome and outpatient careHospital careInflation and pricesLong-term, rehabilitative, and terminal careMarriage and family statusMedicaidMedical educationMedicareMental healthMusculoskeletal and skin diseasesNeurological disordersPrescription drugsSex and reproductive healthState and local courtsState and local finance

IMPROVE Act

USA115th CongressHR-7217| House 
| Updated: 12/12/2018
Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act or the IMPROVE Act This bill establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate. The bill also makes a series of reductions relating to federal Medicaid expenditures. Among other changes, the bill reduces the federal matching rate for states that do not have required asset-verification programs for determining Medicaid eligibility. Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly). Finally, the bill excludes specified wheelchairs and associated accessories from Medicare's competitive acquisition program (in which rates are set through a competitive bidding program rather than by an established fee schedule).

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 6, 2018
Introduced in House
Dec 6, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 11, 2018
Mr. Barton moved to suspend the rules and pass the bill.
Dec 11, 2018
Considered under suspension of the rules. (consideration: CR H10043-10052)
Dec 11, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 7217.
Dec 11, 2018
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Dec 11, 2018
Considered as unfinished business. (consideration: CR H10083)
Dec 11, 2018
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 400 - 11 (Roll no. 428). (text: CR H10043-10047)
View Vote
Dec 11, 2018
Motion to reconsider laid on the table Agreed to without objection.
Dec 12, 2018
Received in the Senate.
  • December 6, 2018
    Introduced in House


  • December 6, 2018
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • December 11, 2018
    Mr. Barton moved to suspend the rules and pass the bill.


  • December 11, 2018
    Considered under suspension of the rules. (consideration: CR H10043-10052)


  • December 11, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 7217.


  • December 11, 2018
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • December 11, 2018
    Considered as unfinished business. (consideration: CR H10083)


  • December 11, 2018
    On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 400 - 11 (Roll no. 428). (text: CR H10043-10047)
    View Vote


  • December 11, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • December 12, 2018
    Received in the Senate.
Joe Barton

Joe Barton

Republican Representative

Texas

Cosponsors (8)
Brett Guthrie (Republican)Debbie Dingell (Democratic)Gus M. Bilirakis (Republican)Fred Upton (Republican)Gene Green (Democratic)Anna G. Eshoo (Democratic)Kathy Castor (Democratic)Jaime Herrera Beutler (Republican)

Ways and Means Committee, Energy and Commerce Committee

Health

Related Bills

  • S 115-3702: A bill to amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
  • HR 115-7223: To amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Birth defectsBlood and blood diseasesBusiness recordsCardiovascular and respiratory healthChild healthCivil actions and liabilityDisability and paralysisEmergency medical services and trauma careFamily servicesHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth personnelHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesHereditary and development disordersHIV/AIDSHome and outpatient careHospital careInflation and pricesLong-term, rehabilitative, and terminal careMarriage and family statusMedicaidMedical educationMedicareMental healthMusculoskeletal and skin diseasesNeurological disordersPrescription drugsSex and reproductive healthState and local courtsState and local finance